The ins and outs of microRNAs as biomarkers in liver disease and transplantation

Transplant International

Volumn 27, Issue 12, 2014, Pages 1222-1232

  Farid, Waqar R R ^a   Verhoeven, Cornelia J ^a   De Jonge, Jeroen ^a   Metselaar, Herold J ^a   Kazemier, Geert ^b   Van Der Laan, Luc J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

hepatitis B, C infection; ischemia reperfusion injury organ preservation and procurement; molecular diagnostic; outcome liver clinical; solid tumors malignancies and long term compliations

Indexed keywords

MICRORNA; BIOLOGICAL MARKER;

CANCER RECURRENCE; CELL COMMUNICATION; CELL STRESS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; GENE CONTROL; GENE EXPRESSION; GENETIC STABILITY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; RECURRENT DISEASE; REVIEW; BLOOD; CARCINOMA, HEPATOCELLULAR; FORECASTING; GENE EXPRESSION REGULATION; HEPATITIS C, CHRONIC; LIVER DISEASES; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE; RNA STABILITY; TRANSPLANTATION;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FORECASTING; GENE EXPRESSION REGULATION; HEPATITIS C, CHRONIC; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECURRENCE; RNA STABILITY; TISSUE AND ORGAN PROCUREMENT;

EID: 84911132634     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12379     Document Type: Review

References (86)

1. Backman L, Gibbs J, Levy M, et al,. Causes of late graft loss after liver transplantation. Transplantation 1993; 55: 1078.
2. Duffy JP, Kao K, Ko CY, et al,. Long-term patient outcome and quality of life after liver transplantation: analysis of 20-year survivors. Ann Surg 2010; 252: 652.
3. Ambros V,. The functions of animal microRNAs. Nature 2004; 431: 350.
4. Vasilescu C, Rossi S, Shimizu M, et al,. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One 2009; 4: e7405.
5. Tang Y, Luo X, Cui H, et al,. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065.
6. Hezova R, Slaby O, Faltejskova P, et al,. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol 2010; 260: 70.
7. Chen X, Ba Y, Ma L, et al,. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997.
8. Chen Y, Stallings RL,. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007; 67: 976.
9. Mendell JT, Olson EN,. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172.
10. O'Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF,. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 2009; 136: 17.
11. Bonauer A, Carmona G, Iwasaki M, et al,. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710.
12. Liang Y, Ridzon D, Wong L, Chen C,. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.
13. Farid WR, Pan Q, van der Meer AJ, et al,. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012; 18: 290.
14. Verhoeven CJ, Farid WR, de Ruiter PE, et al,. MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. J Hepatol 2013; 59: 1231.
15. Wang K, Zhang S, Marzolf B, et al,. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402.
16. Laterza OF, Lim L, Garrett-Engele PW, et al,. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55: 1977.
17. Scian MJ, Maluf DG, David KG, et al,. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/TA. Am J Transplant 2011; 11: 2110.
18. Shigehara K, Yokomuro S, Ishibashi O, et al,. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 2011; 6: e23584.
19. Mitchell PS, Parkin RK, Kroh EM, et al,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513.
20. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO,. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654.
21. Zernecke A, Bidzhekov K, Noels H, et al,. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal, 2009; 2: ra81.
22. Arroyo JD, Chevillet JR, Kroh EM, et al,. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003.
23. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT,. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423.
24. Barad O, Meiri E, Avniel A, et al,. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 2004; 14: 2486.
25. Chen L, Yan HX, Yang W, et al,. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009; 50: 358.
26. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A,. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648.
27. Hand NJ, Master ZR, Eauclaire SF, Weinblatt DE, Matthews RP, Friedman JR,. The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 2009; 136: 1081.
28. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T,. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735.
29. Krutzfeldt J, Rajewsky N, Braich R, et al,. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685.
30. Castoldi M, Vujic Spasic M, Altamura S, et al,. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest, 2011; 121: 1386.
31. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P,. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577.
32. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al,. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198.
33. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W,. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006; 125: 1111.
34. Leung AK, Sharp PA,. MicroRNA functions in stress responses. Mol Cell 2010; 40: 205.
35. Patella F, Rainaldi G,. MicroRNAs mediate metabolic stresses and angiogenesis. Cell Mol Life Sci 2012; 69: 1049.
36. Kamm RC, Smith AG,. Nucleic acid concentrations in normal human plasma. Clin Chem 1972; 18: 519.
37. Weber JA, Baxter DH, Zhang S, et al,. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733.
38. Turchinovich A, Weiz L, Langheinz A, Burwinkel B,. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223.
39. Pan Q, Ramakrishnaiah V, Henry S, et al,. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2012; 61: 1330.
40. Janas T, Janas T, Yarus M,. Specific RNA binding to ordered phospholipid bilayers. Nucleic Acids Res 2006; 34: 2128.
41. Pigati L, Yaddanapudi SC, Iyengar R, et al,. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010; 5: e13515.
42. Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK,. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res 2010; 38: 215.
43. Fichtlscherer S, De Rosa S, Fox H, et al,. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677.
44. van der Meer AJ, Farid WR, Sonneveld MJ, et al,. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013; 20: 158.
45. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L,. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937.
46. Roderburg C, Urban GW, Bettermann K, et al,. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53: 209.
47. Roderburg C, Mollnow T, Bongaerts B, et al,. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7: e32999.
48. Gui J, Tian Y, Wen X, et al,. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011; 120: 183.
49. Xu J, Wu C, Che X, et al,. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136.
50. Li LM, Hu ZB, Zhou ZX, et al,. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010; 70: 9798.
51. Zhou J, Yu L, Gao X, et al,. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781.
52. Li J, Wang Y, Yu W, Chen J, Luo J,. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406: 70.
53. de Mare-Bredemeijer EL, Mancham S, Utomo WK, et al,. Genetic polymorphisms in innate immunity receptors do not predict the risk of bacterial and fungal infections and acute rejection after liver transplantation. Transpl Infect Dis 2013; 15: 120.
54. Dubbeld J, van Hoek B, Ringers J, et al,. Biliary Complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcome from a single center. Ann Surg, 2014 (ahead of print).
55. Farid WR, de Jonge J, Slieker JC, et al,. The importance of portal venous blood flow in ischemic-type biliary lesions after liver transplantation. Am J Transplant 2011; 11: 857.
56. van den Berg-Emons RJ, van Ginneken BT, Nooijen CF, et al,. Fatigue after liver transplantation: effects of a rehabilitation program including exercise training and physical activity counseling. Phys Ther 2014; 94: 857.
57. Farid WR, de Jonge J, Zondervan PE, et al,. Relationship between the histological appearance of the portal vein and development of ischemic-type biliary lesions after liver transplantation. Liver Transpl 2013; 19: 1088.
58. Tjon AS, Sint Nicolaas J, Kwekkeboom J, et al,. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl, 2010; 16: 837.
59. Hu J, Wang Z, Tan CJ, et al,. Plasma microRNA, a potential biomarker for acute rejection after liver transplantation. Transplantation 2013; 95: 991.
60. Verhoeven CJ, Farid WR, de Jonge J, Metselaar HJ, Kazemier G, van der Laan LJ,. Biomarkers to assess graft quality during conventional and machine preservation in liver transplantation. J Hepatol, 2014 (ahead of print).
61. Lankisch TO, Voigtlander T, Manns MP, Holzmann A, Dangwal S, Thum T,. MicroRNAs in bile of patients with biliary strictures after liver transplantation. Liver Transpl 2014; 20: 673.
62. Verhoeven CJ, Metselaar HJ, van der Laan LJ,. Barking up the wrong tree: microRNAs in bile as markers for biliary complications. Liver Transpl 2014; 20: 637.
63. Joshi D, Salehi S, Brereton H, et al,. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. Liver Transpl 2013; 19: 383.
64. Gehrau RC, Mas VR, Villamil FG, et al,. MicroRNA signature at the time of clinical HCV recurrence associates with aggressive fibrosis progression post-liver transplantation. Am J Transplant 2013; 13: 729.
65. Gelley F, Zadori G, Nemes B, et al,. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis. J Gastroenterol Hepatol 2014; 29: 121.
66. Ravaioli M, Ercolani G, Neri F, et al,. Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol 2014; 20: 5345.
67. Han ZB, Zhong L, Teng MJ, et al,. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012; 6: 445.
68. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH,. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012; 138: 153.
69. Chen H, Miao R, Fan J, et al,. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis 2013; 30: 651.
70. Sato F, Hatano E, Kitamura K, et al,. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011; 6: e16435.
71. Chen HY, Han ZB, Fan JW, et al,. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol 2012; 29: 1859.
72. Cuk K, Zucknick M, Heil J, et al,. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 2013; 132: 1602.
73. Kubiczkova L, Kryukov F, Slaby O, et al,. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2013; 99: 511.
74. Li A, Yu J, Kim H, et al,. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013; 19: 3600.
75. Nguyen HC, Xie W, Yang M, et al,. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013; 73: 346.
76. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L,. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther 2013; 14: 1104.
77. Shen J, Wang A, Wang Q, et al,. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev 2013; 22: 2364.
78. Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q,. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014; 25: 346.
79. Thomson DW, Bracken CP, Goodall GJ,. Experimental strategies for microRNA target identification. Nucleic Acids Res 2011; 39: 6845.
80. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L,. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 2010; 78: 838.
81. Camussi G, Deregibus MC, Tetta C,. Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information. Curr Opin Nephrol Hypertens 2010; 19: 7.
82. Quesenberry PJ, Aliotta JM,. The paradoxical dynamism of marrow stem cells: considerations of stem cells, niches, and microvesicles. Stem Cell Rev 2008; 4: 137.
83. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ,. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487.
84. Yuan JY, Wang F, Yu J, Yang GH, Liu XL, Zhang JW,. MicroRNA-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells. J Cell Mol Med 2009; 13: 4551.
85. Zhang Y, Jia Y, Zheng R, et al,. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56: 1830.
86. Hinkel R, Penzkofer D, Zuhlke S, et al,. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013; 128: 1066.